Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ENDURANCE-4: Glecaprevir/Pibrentasvir in HCV GT 4, 5, or 6
NCT02636595Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Nov 2015
- Primary completion
- Oct 2016
- Modality
- Reversible Covalent Inhibitors, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 3 trial of glecaprevir in hepatitis C (HCV), sponsored by AbbVie Inc.. Started Nov 2015; status: completed.
02
Drugs
glecaprevir
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT02636595.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02636595.